Patent · US Active

Antagonizing CD73 antibody

US11312785B2 · kind B2 · utility

0Cited by

2References

45Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Irmgard Maria Rita Hofmann · Wien, AT
Jennifer Ahlberg · Redding, US
Rajkumar Ganesan · Blue Bell, US
Priyanka GUPTA · Danbury, US
Sven Mostboeck · Wien, AT
Simon Plyte · Como, IT
Otmar Schaaf · Wien, AT
Chia-Hung Tsai · Danbury, US
Melanie WURM · Wien, AT
Markus ZETTL · Wien, AT
Jark BOETTCHER · Wien, AT
Bruna De Andrade Pereira · Biberach an der Riß, DE

Key dates

Filing date	May 13, 2019
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Jan 26, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel antagonizing antibodies for CD73. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.